Sanofi, Janssen Team Up To Develop And Commercialize The Vaccine Candidate For Extraintestinal Pathogenic E. coli (9-valent) Developed By Janssen, Currently In Phase 3
Portfolio Pulse from Benzinga Newsdesk
Sanofi and Janssen have partnered to develop and commercialize a vaccine candidate for extraintestinal pathogenic E. coli, currently in Phase 3. The vaccine is being developed by Janssen.
October 03, 2023 | 6:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Janssen, a subsidiary of Johnson & Johnson, is developing a vaccine candidate for extraintestinal pathogenic E. coli, currently in Phase 3, in partnership with Sanofi.
The partnership with Sanofi for the development and commercialization of a new vaccine candidate could potentially enhance Janssen's, and by extension Johnson & Johnson's, product portfolio and revenue stream, leading to a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Sanofi has entered into a partnership with Janssen to develop and commercialize a vaccine candidate, which could potentially boost its product portfolio.
The partnership with Janssen for the development and commercialization of a new vaccine candidate could potentially enhance Sanofi's product portfolio and revenue stream, leading to a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50